questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Cyclic Nucleotide-Regulated Protein Kinases
Cyclic GMP-Dependent Protein Kinases
Cyclic GMP-Dependent Protein Kinases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Healthcare Failure Mode and Effect Analysis
Diagnostic
5
GMP cyclique
Tests de laboratoire
Kinases
Essais enzymatiques
Symptômes
5
Troubles neurologiques
Kinases
Fonction cardiaque
Kinases
Maladies cardiovasculaires
Kinases
Troubles de l'humeur
Kinases
Traitements
5
Thérapies géniques
Kinases
Plantes médicinales
Kinases
Complications
5
Troubles de la coagulation
Kinases
Troubles respiratoires
Kinases
Facteurs de risque
5
Facteurs de risque
Kinases
Antécédents familiaux
Kinases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cyclic GMP-Dependent Protein Kinases : Questions médicales les plus fréquentes",
"headline": "Cyclic GMP-Dependent Protein Kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cyclic GMP-Dependent Protein Kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-11",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cyclic GMP-Dependent Protein Kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cyclic Nucleotide-Regulated Protein Kinases",
"url": "https://questionsmedicales.fr/mesh/D017867",
"about": {
"@type": "MedicalCondition",
"name": "Cyclic Nucleotide-Regulated Protein Kinases",
"code": {
"@type": "MedicalCode",
"code": "D017867",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.150"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cyclic GMP-dependent protein kinase type I",
"alternateName": "Cyclic GMP-Dependent Protein Kinase Type I",
"url": "https://questionsmedicales.fr/mesh/D062965",
"about": {
"@type": "MedicalCondition",
"name": "Cyclic GMP-dependent protein kinase type I",
"code": {
"@type": "MedicalCode",
"code": "D062965",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.150.150.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cyclic GMP-dependent protein kinase type II",
"alternateName": "Cyclic GMP-Dependent Protein Kinase Type II",
"url": "https://questionsmedicales.fr/mesh/D062967",
"about": {
"@type": "MedicalCondition",
"name": "Cyclic GMP-dependent protein kinase type II",
"code": {
"@type": "MedicalCode",
"code": "D062967",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.150.150.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Cyclic GMP-Dependent Protein Kinases",
"alternateName": "Cyclic GMP-Dependent Protein Kinases",
"code": {
"@type": "MedicalCode",
"code": "D017869",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Fengyang Li",
"url": "https://questionsmedicales.fr/author/Fengyang%20Li",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Ute Römling",
"url": "https://questionsmedicales.fr/author/Ute%20R%C3%B6mling",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Stepan Gambaryan",
"url": "https://questionsmedicales.fr/author/Stepan%20Gambaryan",
"affiliation": {
"@type": "Organization",
"name": "Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, Saint Petersburg 194223, Russia."
}
},
{
"@type": "Person",
"name": "Roshni R Kharadi",
"url": "https://questionsmedicales.fr/author/Roshni%20R%20Kharadi",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, Michigan, USA."
}
},
{
"@type": "Person",
"name": "George W Sundin",
"url": "https://questionsmedicales.fr/author/George%20W%20Sundin",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, Michigan, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Application of healthcare failure mode and effect analysis in controlling surgical instrument packaging defects.",
"datePublished": "2022-11-16",
"url": "https://questionsmedicales.fr/article/36385494",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-24282-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Using Failure Mode and Effect Analysis to Identify Potential Failures in a Psychiatric Hospital Emergency Department.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37162153",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PTS.0000000000001127"
}
},
{
"@type": "ScholarlyArticle",
"name": "Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer.",
"datePublished": "2022-11-22",
"url": "https://questionsmedicales.fr/article/36497503",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph192315428"
}
},
{
"@type": "ScholarlyArticle",
"name": "Failure modes and effects analysis study for accelerator-based Boron Neutron Capture Therapy.",
"datePublished": "2022-12-05",
"url": "https://questionsmedicales.fr/article/36412161",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mp.16104"
}
},
{
"@type": "ScholarlyArticle",
"name": "Failure mode and effects analysis of telehealth service of minority elderly for sustainable digital transformation.",
"datePublished": "2022-08-11",
"url": "https://questionsmedicales.fr/article/35973373",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.compbiomed.2022.105950"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cyclic Nucleotide-Regulated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D017867"
},
{
"@type": "ListItem",
"position": 7,
"name": "Cyclic GMP-Dependent Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D017869"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cyclic GMP-Dependent Protein Kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cyclic GMP-Dependent Protein Kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cyclic GMP-Dependent Protein Kinases",
"description": "Comment diagnostiquer une dysfonction des kinases cGMP ?\nQuels tests sont utilisés pour mesurer le cGMP ?\nQuels symptômes indiquent un problème avec les kinases cGMP ?\nLes tests génétiques sont-ils utiles pour les kinases cGMP ?\nComment évaluer l'activité des kinases cGMP ?",
"url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Healthcare+Failure+Mode+and+Effect+Analysis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cyclic GMP-Dependent Protein Kinases",
"description": "Quels sont les symptômes d'une déficience en kinases cGMP ?\nLes troubles neurologiques sont-ils liés aux kinases cGMP ?\nComment les kinases cGMP affectent-elles la fonction cardiaque ?\nY a-t-il des symptômes spécifiques aux maladies liées aux kinases cGMP ?\nLes troubles de l'humeur peuvent-ils être liés aux kinases cGMP ?",
"url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Healthcare+Failure+Mode+and+Effect+Analysis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cyclic GMP-Dependent Protein Kinases",
"description": "Comment prévenir les troubles liés aux kinases cGMP ?\nL'alimentation influence-t-elle les kinases cGMP ?\nLe stress a-t-il un impact sur les kinases cGMP ?\nLes examens réguliers sont-ils importants ?\nL'exercice physique aide-t-il à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Healthcare+Failure+Mode+and+Effect+Analysis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cyclic GMP-Dependent Protein Kinases",
"description": "Quels traitements ciblent les kinases cGMP ?\nLes médicaments augmentant le cGMP sont-ils efficaces ?\nComment les thérapies géniques peuvent-elles aider ?\nY a-t-il des traitements naturels pour les dysfonctionnements cGMP ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Healthcare+Failure+Mode+and+Effect+Analysis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cyclic GMP-Dependent Protein Kinases",
"description": "Quelles complications peuvent survenir avec des dysfonctionnements cGMP ?\nLes troubles de la coagulation sont-ils liés aux kinases cGMP ?\nY a-t-il des risques de cancer associés aux kinases cGMP ?\nLes maladies rénales peuvent-elles être influencées par cGMP ?\nLes troubles respiratoires sont-ils liés aux kinases cGMP ?",
"url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Healthcare+Failure+Mode+and+Effect+Analysis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cyclic GMP-Dependent Protein Kinases",
"description": "Quels sont les facteurs de risque pour les dysfonctionnements cGMP ?\nL'âge influence-t-il la fonction des kinases cGMP ?\nLe mode de vie sédentaire est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Healthcare+Failure+Mode+and+Effect+Analysis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des kinases cGMP ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques et des analyses génétiques peuvent être utilisés pour évaluer la fonction des kinases cGMP."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour mesurer le cGMP ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages immunologiques et des tests enzymatiques peuvent mesurer les niveaux de cGMP dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec les kinases cGMP ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme des troubles cardiovasculaires ou neurologiques peuvent indiquer un dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour les kinases cGMP ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les kinases cGMP."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des kinases cGMP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité peut être évaluée par des essais enzymatiques spécifiques in vitro."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en kinases cGMP ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles de la circulation sanguine et des problèmes de vision."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux kinases cGMP ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans les kinases cGMP peuvent contribuer à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les kinases cGMP affectent-elles la fonction cardiaque ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles régulent la relaxation et la contraction cardiaque, influençant la pression artérielle."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux maladies liées aux kinases cGMP ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes spécifiques peuvent inclure des douleurs thoraciques et des palpitations."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur peuvent-ils être liés aux kinases cGMP ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre les kinases cGMP et la régulation de l'humeur."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés aux kinases cGMP ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain et surveiller les facteurs de risque cardiovasculaires aide à prévenir."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les kinases cGMP ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut soutenir la fonction des kinases cGMP."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les kinases cGMP ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la signalisation cGMP et la santé cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des dysfonctionnements cGMP."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la signalisation cGMP et la santé globale."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases cGMP ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques et des modulateurs de cGMP sont utilisés pour traiter certaines conditions."
}
},
{
"@type": "Question",
"name": "Les médicaments augmentant le cGMP sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments comme les nitrates et les inhibiteurs de la phosphodiestérase peuvent être efficaces."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques peuvent-elles aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques peuvent corriger des mutations dans les gènes des kinases cGMP."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour les dysfonctionnements cGMP ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent avoir des effets bénéfiques sur la signalisation cGMP."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation saine et l'exercice peuvent améliorer la fonction des kinases cGMP."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des dysfonctionnements cGMP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des maladies cardiovasculaires et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les troubles de la coagulation sont-ils liés aux kinases cGMP ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans les kinases cGMP peuvent affecter la coagulation sanguine."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés aux kinases cGMP ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un lien entre les dysfonctionnements cGMP et le développement du cancer."
}
},
{
"@type": "Question",
"name": "Les maladies rénales peuvent-elles être influencées par cGMP ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les kinases cGMP jouent un rôle dans la régulation de la fonction rénale."
}
},
{
"@type": "Question",
"name": "Les troubles respiratoires sont-ils liés aux kinases cGMP ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la signalisation cGMP peuvent contribuer à des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les dysfonctionnements cGMP ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'hypertension, le diabète et le tabagisme."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la fonction des kinases cGMP ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la signalisation cGMP et la santé cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire peut augmenter le risque de dysfonctionnement des kinases cGMP."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la signalisation cGMP et augmenter les risques de maladies."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiovasculaires peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 06/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
3 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Affiliations :
Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, Saint Petersburg 194223, Russia.
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, Michigan, USA.
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, Michigan, USA.
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular and Cellular Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Veterinary Clinical Pathology and Bio-safety Research Institute, College of Veterinary Medicine, Chonbuk National University, Jeonju, Republic of Korea.
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular and Cellular Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
BK21Plus Program for 21st Century Biomedical Science Leader Development, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
2 publications dans cette catégorie
Publications dans "Cyclic GMP-Dependent Protein Kinases" :
Surgical instrument packaging defects may affect the safety of medical care and patients and waste the hospital workforce, material resources, and financial resources. This study explored the applicat...
Failure mode and effect analysis (FMEA) is a powerful tool for accessing potential failures, but the participants are limited. It has not been used in psychiatric hospitals. Objectives were to impleme...
In this prospective, questionnaire-based study, a multidisciplinary team experienced in ED admissions was trained in FMEA and determined potential failures in the process. They developed a questionnai...
By applying FMEA, we found 6 steps of the ED admission process, with 32 potential failures. Risk priority numbers ranged from 91 to 225. The most notable potential failure identified was during a pati...
Failure mode and effect analysis can be implemented in psychiatric hospitals and can be a useful tool for anticipating potential failures. The number of participants in an FMEA can be increased to inc...
It is crucial to investigate the risk factors inherent in the medication process for cancer patients since improper antineoplastic drug use frequently has serious consequences. As a result, the Severi...
Boron Neutron Capture Therapy (BNCT) has recently been used in clinical oncology thanks to recent developments of accelerator-based BNCT systems. Although there are some specific processes for BNCT, t...
The aim of this study is to provide comprehensive data on the risk of accelerator-based BNCT system to institutions planning to implement an accelerator-based BNCT system....
In this study, failure mode and effects analysis (FMEA) was performed based on a treatment process map prepared for the accelerator-based BNCT system. A multidisciplinary team consisting of a medical ...
The identified FMs for BNCT were 165 in which 30 and 17 FMs were classified as high risk and very high risk, respectively. Additionally, 71 FMs were accelerator-based BNCT-specific FMs in which 18 and...
This study is the first report for conducting a risk analysis for BNCT using FMEA. Thus, this study provides comprehensive data needed for quality assurance/quality control (QA/QC) in the treatment pr...
Telehealth services are time- and cost-saving solutions for disease management for older adults. Minority older individuals with multiple risk factors have an increasing demand for telehealth services...
An eight-member multidisciplinary team conducted telehealth FMEA to determine risk priority numbers (RPNs). The process included identifying the potential cause and effect failure mode of each step; m...
This study identified 24 risk factors and 34 causes in four major phases with a mean RPN of 90.7: preparation to measure biosignals, measurement of biosignals following instructions from a personal de...
To correct these failure modes, stabilization of the platform, adding to the providers' manpower, and support for government policies are recommended. FMEA identifies and evaluates the potential risks...
There is growing interest among pediatric institutions for implementing iodine-131 (I-131) meta-iodobenzylguanidine (MIBG) therapy for treating children with high-risk neuroblastoma. Due to regulation...
We formed a multidisciplinary team, involving pediatric oncology, radiation oncology, and radiation safety staff. To evaluate the robustness of the therapy workflow and quantitatively assess potential...
A total of 176 failure modes were identified and scored. The majority (94%) of failure modes scored low (RPN <100). The highest risk failure modes were related to training and to drug-infusion procedu...
Through use of FMEA methodology, we successfully identified multiple potential points of failure that have allowed us to proactively mitigate risks when implementing a pediatric MIBG program....
The Global Clinical Trials RTQA Harmonization Group (GHG) set out to evaluate and prioritize clinical trial quality assurance....
The GHG compiled a list of radiotherapy quality assurance (QA) tests performed for proton and photon therapy clinical trials. These tests were compared between modalities to assess whether there was a...
The risk analysis showed that proton and photon therapy shared four out of five of their highest-risk failures (end-to-end anthropomorphic phantom test, phantom tests using respiratory motion, pre-tre...
The identification of high-risk errors associated with clinical trials is valuable to prioritize and reduce errors in radiotherapy and improve the quality of trial data and outcomes, and can be applie...
Proposal of a risk analysis model to diminish negative impact on patient care by preanalytical errors in blood gas analysis (BGA)....
Here we designed a Failure Mode and Effects Analysis (FMEA) risk assessment template for BGA, based on literature references and expertise of an international team of laboratory and clinical health ca...
The FMEA identifies pre-analytical process steps, errors that may occur whilst performing BGA (potential failure mode), possible consequences (potential failure effect) and preventive/corrective actio...
This FMEA model will help health care professionals manage and minimize the risk of preanalytical errors in BGA....
Volumetric-modulated arc therapy for total body irradiation (VMAT-TBI) is a novel radiotherapy technique that has been implemented at our institution. The purpose of this work is to investigate possib...
We formed a multidisciplinary team to map out the complete treatment process of VMAT-TBI following the AAPM TG-100 guidelines. This process map gives a visual representation of the VMAT-TBI workflow f...
We identified a total of 55 sub-processes and 128 FMs from the VMAT-TBI workflow. The top five high-risk FMs were: (1) Prescription and/or OAR constraints changed during planning and not communicated ...
FM and effect analysis was performed to identify high-risk FMs of our VMAT-TBI program. FMEA and FTA were effective in identifying potential FMs and determining the best quality management (QM) measur...
Surgical transfusion has an outsized impact on hospital-based transfusion services, leading to blood product waste and unnecessary costs. The objective of this study was to design and implement a stre...
To address the high rates of surgical blood issue requests and red blood cell (RBC) unit waste at a large academic medical center, a failure modes and effects analysis was used to systematically exami...
The number of perioperative RBC unit issue requests decreased from 358 per month (SD 24) pre-intervention to 282 per month (SD 16) post-intervention (p < .001), resulting in an estimated savings of 8....
Our intervention, designed based on a structured failure modes analysis, achieved sustained reductions in perioperative RBC unit issue orders, returns, and waste, with associated benefits for blood co...